Metformin Augments Panobinostat's Anti-Bladder Cancer Activity by Activating AMP-Activated Protein Kinase - ScienceDirect
The Design, Synthesis, and Evaluation of Hypoxia-Activated Prodrugs of the KDAC Inhibitor Panobinostat - preLights
Post-translational reduction of Sp1 in MM cells by panobinostat. A. The... | Download Scientific Diagram
Cancers | Free Full-Text | HDAC Inhibitors Exert Anti-Myeloma Effects through Multiple Modes of Action | HTML
Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies - Imai - 2016 - Cancer Science - Wiley Online Library
The HDAC inhibitor, panobinostat, induces apoptosis by suppressing the expresssion of specificity protein 1 in oral squamous cell carcinoma
Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies - Imai - 2016 - Cancer Science - Wiley Online Library
Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors | Future Oncology
Panobinostat - an overview | ScienceDirect Topics
Panobinostat - an overview | ScienceDirect Topics
Cancers | Free Full-Text | HDAC Inhibitors Exert Anti-Myeloma Effects through Multiple Modes of Action | HTML
Panobinostat inhibits survival and clonogenicity of human DIPG cells in... | Download Scientific Diagram
Panobinostat profiling in rat tissue in vivo and ex vivo a, Tissue-TPP... | Download Scientific Diagram
Panobinostat mechanism of action: synergy with bortezomib. a Dual... | Download Scientific Diagram
JCI Insight - Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma
Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas
Use of panobinostat in patients with classical Hodgkin lymphoma | International Journal of Hematologic Oncology
Panobinostat - Wikiwand
Salvage therapies in relapsed and/or refractory myeloma: what is curre | OTT
Farydak® (panobinostat) for the Treatment of Multiple Myeloma - Clinical Trials Arena
Farydak® (panobinostat) for the Treatment of Multiple Myeloma - Clinical Trials Arena
Pan-HDAC inhibitor panobinostat, as a single agent or in combination with PI3K inhibitor, induces apoptosis in APL cells: An emerging approach to overcome MSC-induced resistance - ScienceDirect
Panobinostat: a Histone Deacetylase Inhibitor | Personalized Medicine in Oncology
The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair | Leukemia
New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG) | Leukemia
